The company, which trades under the ticker LABT, is positioning its proprietary Bisphosphocin platform as a primary solution to the current stagnation in antibiotic development. Unlike traditional antibiotics, these compounds function by destabilizing bacterial cell membranes in a pH-dependent manner. Initial laboratory data suggests this mechanism not only kills resistant strains rapidly but potentially reduces the likelihood of bacteria evolving further resistance.

Lakewood-Amedex is currently preparing for Phase 2 clinical trials for its lead candidate, Nu-3, specifically targeting infected diabetic foot ulcers. These infections remain a major driver of global hospitalization and amputation rates, exacerbated by the growing prevalence of drug-resistant bacteria. CEO Kelvin Cooper noted that the company’s focus on this clinical application aligns with the broader goals of the PASTEUR legislation, which seeks to revitalize the pipeline for life-saving anti-infective treatments.